Canada · Delayed Price · Currency is CAD Sun Life Financial Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw solid underlying earnings, strong insurance sales growth in Asia and the U.S., and continued asset management expansion. Capital strength remains high despite acquisition-driven LICAT decline, with a dividend increase and renewed buyback reflecting robust cash flow.
-
Earnings per share grew 12% and ROE surpassed 18%, driven by leadership changes and strong regional performance. U.S. dental strategy shifts to optimizing state business and expanding commercial, while Stop-Loss benefits from pricing power. Asset management focuses on organic growth and targeted bolt-ons.
Fiscal Year 2025
-
Q4 2025 saw double-digit earnings growth, strong sales across all regions, and robust capital generation, with underlying net income up 13% year-over-year and a LICAT ratio of 157%. SLC Management exceeded targets, U.S. stop-loss and dental showed improvement, and digital initiatives drove client engagement.
-
Strategic priorities include asset management integration, U.S. dental business improvement, and digital transformation. Strong capital generation supports disciplined M&A and buybacks, with a focus on achieving a 20% ROE target. Asset management and Asian growth drive outperformance.
-
Q3 2025 saw strong earnings growth in Asia, Canada, and asset management, offset by U.S. headwinds from higher claims and pricing lags. Capital position remains robust with a higher dividend and continued share buybacks. U.S. business recovery is expected as repricing and cost actions take effect.
-
A diversified business mix focused on low-capital group benefits and asset management supports a 20% ROE target. U.S. dental faces short-term headwinds, while asset management and Asia drive growth. Strong capital enables flexibility for buybacks and selective M&A.
-
Q2 2025 saw underlying EPS rise 4% and net income top $1 billion, with strong results in Asia, Canada, and U.S. employee benefits. U.S. dental earnings outlook was revised down due to Medicaid uncertainty, but long-term growth targets remain intact.
-
Record underlying net income and EPS growth were driven by strong performance across all segments, with robust capital levels and continued share buybacks. Asset management, Canada, and Asia delivered standout results, while the U.S. business stabilized. Dividend was increased by 5%.
-
Leadership emphasized strategic pivots, strong culture, and disciplined capital deployment. U.S. group business faces manageable risks, with repricing underway to address claim severity. Asset management growth is driven by upcoming buyouts and platform integration, while surplus assets are being repositioned for better yields.
Fiscal Year 2024
-
Q4 results showed strong performance in Canada, Asia, and asset management, offset by higher U.S. stop-loss claim severity and one-time items. Full-year underlying net income rose 3% to CAD 3.9 billion, with a robust capital position and ongoing share buybacks. LICAT ratio remained strong at 152%.
-
Raised medium-term targets to 10%+ EPS growth and 20%+ ROE, driven by a diversified, capital-light business mix and strong asset management and digital capabilities. Regional businesses in Canada, the U.S., and Asia each have ambitious growth plans, while digital and GenAI initiatives underpin efficiency and client impact.
-
Q3 2024 saw record earnings, strong capital, and broad-based growth, with EPS up 11% and AUM at $1.5 trillion. U.S. dental repricing and restructuring savings are on track, while asset management and Asia delivered solid results.
-
Q2 delivered a strong rebound with high-quality earnings, robust growth in Canada and Asia, and resilient U.S. performance outside dental, which faces temporary Medicaid challenges. Asset management and alternatives remain strategic priorities, with capital strength supporting buybacks and future investments.
-
Record underlying net income and EPS growth were driven by strong sales in Canada and Asia, while restructuring initiatives target over CAD 200 million in cost savings by 2026. U.S. Dental recovery is expected to accelerate, and capital strength remains robust.